Aurobindo Pharma arm Acrotech Biopharma launches ADQUEY in US dermatology market

Drug firm Aurobindo Pharma Ltd on Wednesday (September 30) said its biopharmaceutical arm Acrotech Biopharma Inc. has launched ADQUEY (difamilast 1%) ointment in the US for the treatment of mild-to-moderate atopic dermatitis in adults and paediatric patients aged 2 years and older. ADQUEY is a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor. The product will compete in…

Read More